Recently, patients with metastatic desmoplastic melanoma (DM) have been shown to respond more favorably to anti-PD1/PD-L1 therapy than other melanoma subtypes. Given this, we evaluated PD-L1/2 expression in primary DM samples and correlated these with subtype, CD8+ lymphocyte status, histopathological prognosticators, and select genetic alterations. Eighty-six (36 mixed DM, 50 pure DM) archival annotated samples met inclusion criteria and were immunohistochemically semiquantitatively evaluated. Per established criteria, for PD-L1/L2, cases with ⩾ 5% tumoral expression, and for CD8, cases with a predominantly peri/intratumoral CD8+ infiltrate were scored positive. Univariate analysis (chi-square and Wilcoxon) identified potential confounders and a nested case-control study was accomplished using multiple logistic regression. For PD-L1, 49% of cases were positive and 71% of cases with thickness 44 mm were positive; PD-L1 expression differed by median depth (3.29 mm, interquartile range = 3.58 mm for PD-L1 positives vs 1.75 mm, interquartile range = 2.04 mm for PD-L1 negatives, P = 0.0002) and was linearly associated with increasing depth of invasion (P = 0.0003). PD-L1-positive cases were more likely to display CD8+ lymphocytes (60 vs 28% P = 0.0047).The presence of CD8+ lymphocytes correlated significantly with depth of invasion 41 mm (P = 0.022). On multivariate analysis, PD-L1 was 6.14 × more likely to be expressed in mixed DM than pure DM (P = 0.0131), CD8+ staining was 6.22 × more likely in PD-L1 positive cases than in PD-L1 negative (P = 0.0118), and tumor depth was associated with greater odds of PD-L1 expression (OR = 1.61, P = 0.0181). PD-L2 expression was observed in 48% of cases but did not correlate with any variables. Correlation of tumoral PD-L1 with increased depth and CD8+ lymphocytes implicates the tumoral immune microenvironment with advancing disease in DM. Enhanced tumoral PD-L1 expression in the mixed cytomorphological variant provides an insight into the differential pathogenesis of the subtypes and suggests that these patients are likely better candidates for anti-PD/PD-L1 therapy.
Overall, the prognosis of DM is distinct from that of non-DM s and is impacted by its histopathological classification into either the pure or mixed subtypes. 3 If 490% of the tumor is composed of cells with a spindled cytomorphology, then it is considered pure DM, and if the spindled cytomorphology is o 90% with the rest composed of tumoral cells with an epithelioid cytomorphology, it is considered mixed DM. 3, 4 This distinction is of clinical relevance as it is now understood that the mixed DM subtype is more prone to undergo metastasis than pure DM and is associated with increased mortality. 3, 5 In addition to prognostic differences between mixed DM and pure DM, underlying differences in the tumor biology exist that may, in part, explain the different clinical behaviors of the subtypes. [6] [7] [8] [9] [10] Notably, pure DM appears to lack BRAF-V600E and other common driver mutations while mixed DM can be BRAF mutated, albeit at a reduced rate compared with more common melanoma variants. 6, 10 These differences present important considerations in the therapeutic management of advanced cases of DM.
The lower incidence of BRAF mutations in both mixed DM and pure DM compared with other melanoma variants suggests that they may be less amenable to available targeted therapies. Currently, immunomodulatory therapies that involve disrupting the programed death ligand-1 (PD-L1, CD274, B7-H1) and programmed death receptor (PD1, CD273, B7-DC) axis present a promising alternative to targeted therapy in non-BRAF mutated melanomas. Under non-pathological conditions, the surface glycoprotein PD-L1 is expressed by antigenpresenting cells (APCs) and serves as an 'immune checkpoint' providing inhibitory input to cytotoxic T lymphocytes (CD8) and other immune effector cells via the PD1 receptor. The resultant reduction in CD8+ lymphocyte proliferation serves to promote self-tolerance. 11 Tumors that express PD-L1 are able to use this mechanism to evade an antitumor immune response. Additionally, in some cancers tumor-infiltrating monocytes may be the primary source of inhibitory PD-L1 signaling. 12 The disruption of PD1/PD-L1 signaling by therapeutic monoclonal antibodies (Nivolumab and Pembrolizumab) has resulted in durable responses and significant improvements in overall and progression-free survival in advanced melanoma, underscoring the clinical importance of this pathway. [13] [14] [15] Attempts to discover predictive markers of response to anti-PD1/PD-L1 therapy have revealed the importance of preexisting CD8+ tumor-infiltrating lymphocytes (tumorinfiltrating lymphocytes) and tumoral PD-L1 expression in this regard. [16] [17] [18] Notably, Taube et al 18 reported that tumoral PD-L1 expression was expressed in 53% of melanomas biopsied (type not specified) and that positive tumoral PD-L1 expression (membranous expression in ≥ 5% of melanoma cells) correlated significantly with clinical benefit to anti-PD1/PD-L1 therapy. These findings highlight the important role the use of immunohistochemistry to evaluate PD-L1 expression and CD8+ tumor-infiltrating lymphocyte status is likely to have in selecting candidates for PD1/L1 blockade.
Recently, in a retrospective analysis of patients treated with anti-PD1/PD-L1 therapies it was shown that patients with metastatic DM have higher response rates than metastases from other variants of melanoma. 19 However, information regarding patterns of pretreatment PD-L1 expression in DM and its relationship to the pure DM and mixed DM subtypes does not, to date, exist. Given this, we sought to evaluate patterns of both tumoral PD-L1 and PD-L2 (a homologous surface glycoprotein to PD-L1 normally limited to macrophages and dendritic cells) in a cohort of primary DM samples. Additionally, we sought to correlate tumoral PD-L1/L2 expression to CD8+ tumor-infiltrating lymphocyte status as well as established histopathological prognosticators. Finally, select genetic parameters: an activating polymorphism in the glial cell line-derived neurotrophic factor (GDNF) tyrosine receptor kinase (RET) at codon G691S (RETp) and telomerase reverse transcripter (TERT) mutations, which have been implicated as genetic drivers in DM, 9, 10 were evaluated for potential correlations with tumoral PD-L1/L2 expression.
Materials and methods
In this IRB-approved study, archival annotated (BRAF, RETp, and TERT) tissue samples with a diagnosis of primary DM were evaluated and 86 cases identified as fulfilling the criteria for inclusion (sufficient tissue for immunohistochemical analyses). Cases were subclassified as mixed DM or pure DM based on the criteria established by George et al. 5 Briefly, cases in which 490% of the tumor displayed a desmoplastic morphology were categorized as pure DM while cases in which 10-90% had a conventional morphology were classified mixed DM. All patient data were de-identified. Histological sections of all samples were reviewed by two board-certified dermatopathologists (initial sign-out on all was performed by a dermatopathologist and all cases re-reviewed and the diagnosis confirmed by the senior author, MM).
Immunohistochemical Analysis
Formalin-fixed, paraffin-embedded tissue from primary DM s (n = 86) were baked at 65°C for 30 min. Antibodies used were as follows: PD-L1, clone SP263, obtained predilute from Ventana (Ventana Medical Systems, Tuscon, AZ, USA); PD-L2, clone no. 176611 (R&D Systems, Minneapolis, MN, USA) used at a dilution of 1:2000; and CD8, clone SP57 obtained predilute from Ventana Medical Systems (Ventana). For PD-L1, sections were immunostained using Ventana Optiview, while for PD-L2 and CD8, immunostaining was performed using Ventana Ultraview, UV-DAB. All immunostained slides were reviewed by and scored by the senior author in a blinded manner.
For both PD-L1 and PD-L2, positive scoring was determined using previously established cutoffs that have been suggested to predict response to PD1/PD-L1 blockade. 18, 20 Briefly, percentages of tumor cells displaying membranous staining were quantified as either o 5%, 5%, 45-20%, 420-50%, or 450% of the tumor bulk and then each case was assigned a score of 0-4, respectively. Cases with a score ≥ 1 were considered positive. CD8+ lymphocyte status was determined by semiquantitative scoring of stained immune infiltrates. Specifically, a score of 0-3 was assigned to each case, where 0 = no immune infiltrate present, 1 = perivascular infiltration only, 2 = perivascular+peritumoral and/or interstitial infiltration, and 3 = diffuse, tumor obscuring infiltration. Scores of 2 or 3 were considered positive for CD8+ lymphocyte status. Formalin-fixed paraffinembedded tissue blocks of human placenta (PD-L1) and tonsil (PD-L2 and CD8) were used as positive controls.
Statistical Analysis
Differences in cohort demographic, histopathological variables, and genetic mutations were stratified by PD-L1, PD-L2, and CD8+ tumor-infiltrating lymphocyte status. To ascertain the relationship between each of the two PD ligands, CD8+ tumor-infiltrating lymphocyte status and desmoplastic subtype, a univariate analysis was used to identify potential confounders where cohort characteristics differed by both the PD-L1/2 expression and CD8+ tumorinfiltrating lymphocyte status. P-values were generated using Pearson's chi-square where expected frequencies exceeded 5, otherwise a Fisher's exact was used. The associations between DM thickness and expression of PD-L1 and PD-L2 were separately compared using an exact Wilcoxon to compare median thickness. A Mantel-Haenszel chi-square was used to test for linear trend by tumor depth.
Multivariable logistic regression was used to control for any potential confounders of PD-L1/2 expression, DM subtype, CD8+ tumor-infiltrating lymphocyte status, and other histopathological variables. A likelihood ratio test was used to check the overall fitness of the multivariable logistic model. Confounding was considered to be present if two mutually associated factors were also both correlated with the outcome of interest or where inclusion of both factors in a multivariable logistic model changed the odds ratio (percent confounding) by 410%. All statistical analyses were two-sided at alpha of 0.05 and carried out in SAS (SAS/STAT User's Guide, Version 9.4; SAS Institute, Cary, NC, USA).
Results

Clinical and Histopathological Data
Of the 86 cases of primary DM s studied, 58 were male and 28 were female. The median age at the time of diagnoses was 71 (interquartile range = 68) years. Regarding anatomical location, 48 (55%) came from the head and neck while 38 (45%) were from nonhead-and-neck locations. Overall, 50 cases were classified as pure DM (58%) while 36 cases were classified as mixed DM (42%). Per previously established criteria, cases of mixed DM were further subclassified into mixed DM-DM predominant with the DM component being at least 50% but o 90% and mixed DM-conventional melanoma predominant, with the DM component constituting 410% but o 50%. 5 Using these cutoffs, 14 of the 36 mixed DM cases were of the mixed DM-desmoplastic predominant subtype and 22 were of the mixed DM-conventional melanoma predominant subtype. In total, 74 cases (86%) presented with a maximum depth of invasion 41 mm with the most frequent AJCC thickness observed being 2-4 mm (38% of cases). A junctional component was absent in 31 (36%), ulceration was present in 7 (8%), mitotic figures were identified in 54 (63%), host response PD-L1 expression in desmoplastic melanoma was identified in 32 (37%), and perineural invasion was observed in 49 (57%) of cases. Of genetic variables previously annotated, 4 cases (5%) exhibited mutations in BRAF, 21 exhibited polymorphisms in RET (RETp, 28%), and 25 exhibited TERT promoter mutations (35%).
PD-L1 Expression
The overall distribution with regards to tumoral PD-L1 expression was as follows: 43 (51%) displayed o 5% expression, 20 (24%) displayed 5% expression, 2 (2%) displayed 5-20% expression, 7 (8%) displayed 420-50% expression, and 13 (15%) displayed 450% expression (representative examples in Figures 1 and 2 ). Using previously established cutoffs that have been suggested to predict response to PD1/PD-L1 blockade, 42 of the 85 cases (49%, expression data unavailable from 1 case) were scored positive for PD-L1 expression.
On univariate analysis, PD-L1 expression was associated with a greater depth of invasion as measured by multiple criteria (Table 1) . Notably, of all cases that expressed PD-L1, only 1 (2%) had a greatest depth of ≤ 1 mm, compared with 11 (25%) of PD-L1-negative cases (P = 0.0034). When evaluated by AJCC guidelines, PD-L1 showed a significant linear association with increasing depth (P = 0.0028; linear trend, P = 0.0003). Additionally, the median depths of DMs with tumoral PD-L1 expression were significantly greater than those with absent PD-L1 expression (median = 3.29, interquartile range = 1.75 vs median = 1.75, interquartile range = 2.04; P = 0.0002). PD-L1 expression was associated with perineural invasion, with 31 (65%) of PD-L1-positive cases displaying perineural invasion compared with 17 (35%) of PD-L1-negative cases (P = 0.0014). In terms of cytomorphology, mixed DM demonstrated 1.5 times the rate of PD-L1 expression compared with pure DM (61 vs 41%; P = 0.06) before controlling for potential confounders. Although not achieving statistical significance, host response (59% in PD-L1 positive vs 41% in PD-L1 negative cases; P = 0.1534) and TERT mutational status (67% mutated in PD-L1 positive vs 33% in PD-L1 negative cases; P = 0.1827) were found to be marginally (Table 2) . Overall, DM subtype, depth, perineural invasion, host response, CD8+ tumor-infiltrating lymphocyte expression, and TERT promoter mutation status predicted PD-L1 expression (χ 2 = 33.62, df = 6, P o 0.0001). DM thickness was included in the logistic regression as a continuous measurement owing to a paucity of PD-L1-positive samples o 1 mm. When controlling for these potential cofounders, the mixed DM variant was 6.14 times as likely to express PD-L1 than the pure variant (P = 0.0131) and cases with a positive CD8+ lymphocyte status were 6.22 times as likely to express PD-L1 than those cases in which CD8+ staining was absent (P = 0.0118). A 1-mm increase in tumor depth was associated with 1.61-fold greater odds of PD-L1 expression (P = 0.0181). The association between PD-L1 expression and perineural invasion was not significant after controlling for potential cofounders (P = 0.13).
PD-L2 Expression
Using the same cutoffs as described for PD-L1, expression of PD-L2 was observed in 41/79 (52%, expression data unavailable for 7 cases) of samples. The overall distribution with regards to PD-L2 cutoffs was as follows: 38 (48%) displayed o 5% expression, 24 (30%) displayed 5% expression, 10 (13%) displayed 5-20% expression, 5 (6%) displayed 420-50% expression, and 2 (3%) displayed 450% expression.
Although not achieving statistical significance, on univariate analysis PD-L2 was marginally associated with ulceration, and its expression was observed in 86% of ulcerated cases vs 49% of non-ulcerated (P = 0.0667) ( Table 1) . PD-L2 was not significantly associated with any of the histopathological variables or genetic variables analyzed. When controlling for potentially confounding variables in a multivariable regression model, PD-L2 remained unassociated with ulceration (OR = 6.81, P = 0.0874). On univariate analysis, CD8+ tumor-infiltrating lymphocyte status was associated with a tumor thickness 41 mm with 51 (70%) of DMs with a maximum depth 41 mm having positive CD8+ tumor-infiltrating lymphocyte status vs 4 (33%) of DMs with a maximum depth ≤ 1 mm (P = 0.0217) ( Table 3) . Host response as seen on H&E was also associated with CD8+ tumor-infiltrating lymphocyte status as 26 (81%) of DMs with an observed host response scored positive for CD8+ tumor-infiltrating lymphocyte vs 29 (53%) of DMs without an observed host response (P = 0.0187). CD8+ tumor-infiltrating lymphocyte status was not associated with any other histopathological or genetic variable analyzed.
Although both tumor depth and host response were associated with CD8 tumor-infiltrating lymphocyte expression, there was no empirical evidence of confounding. DM tumors 41 mm were no more likely than those ≤ 1 mm to have shown a host response (3/12 vs 29/74; P = 0.5221). Furthermore, a subanalysis, comparing a multiple logistic to simple logistic regression, indicated that neither was confounding the other clinicopathological factor's association with CD8+ tumor-infiltrating lymphocyte by 410%.
Discussion
It is increasingly understood that DM presents with a distinct set of underlying genetic and phenotypic abnormalities when compared with conventional melanomas. 21 Furthermore, there appear to be differences in the pattern of driver mutations seen between the pure and mixed DM variants. 6,9,10 These differences have important therapeutic and prognostic implications. Notably, the well-documented reduced rate of BRAF mutations in DM (only 4/75 cases had BRAF mutations in the present study) compared with other melanoma variants indicates that patients with DM are poor candidates for BRAFtargeted therapies. 10, 21 However, the recent work by Shain et al 21 has shown in a study of 42 cases of DM that the average overall mutational burden is one of the highest observed in any cancer type (62 mutations/Mb). Given that successful response to anti-CTLA4 immune-checkpoint blockade in melanoma has been shown to be associated with the expression of neo-antigens, the products of mutated genes displayed by tumor cells on MHC class 1 surface proteins, some have hypothesized that the increased mutational burden in DM will be associated with an enhanced response to anti-PD1/PD-L1 therapy. [22] [23] [24] In keeping with this, one report from a cohort of 1000 metastatic melanoma patients treated with anti-PD1/ PD-L1 antibodies has shown that patients with metastatic DM had a better response rate compared with the overall cohort. 19 Further supporting a role for mutational burden in predicting response to anti-PD1/PD-L1 therapy is the recent findings by Madore et al 25 that, in the setting of stage III melanoma lymph node biopsies, PD-L1-negative status is associated with a lower mutational burden.
In an effort to further elucidate the therapeutically relevant phenotypic characteristics that define DM, as well the functional differences between the pure and mixed variant, we sought to evaluate patterns of tumoral PD-L1/PD-L2 expression and CD8+ tumorinfiltrating lymphocyte status in a cohort of DMs. We found that 42/85 (49%) of the DMs studied expressed tumoral PD-L1 in ≥ 5% of cells. A recent study by Kakavand et al 26 in 60 patients with metastatic melanoma (2 of which were DM) found that 43% of the cases studied expressed tumoral PD-L1 using a cutoff of ≥ 1% tumoral expression for positivity. This is similar to an earlier study by Madore et al 27 also using the ≥ 1% tumoral PD-L1 expression cutoffs which found that 51% of the 43 a CD8+ expression data unavailable for n = 1 case. b P-values were generated using Pearson's chi-square where expected frequencies exceeded 5, otherwise a Fisher's exact was used. P-values were considered significant when o0.05 and are indicated in bold. c BRAFsequencing data unavailable for n = 11 samples. d RET sequencing data unavailable for n = 11 samples. e TERT sequencing data unavailable for n = 15 samples.
previous observations, suggest that DM as a whole displays similar rates of PD-L1 expression to conventional melanomas. In melanoma, the prognostic meaning of tumoral PD-L1 expression in the absence of immunotherapy is equivocal. In the setting of advanced stage melanoma, multiple studies have shown that tumors lacking PD-L1 expression have worse outcomes. 28, 29 However, others have shown that tumoral PD-L1 expression is a poor prognostic indicator. [30] [31] [32] Therefore, it is difficult to draw a definitive conclusion about the prognostic value of PD-L1 expression in DM on its own. Even so, in the present study we observed significant correlations between tumoral PD-L1 expression and measurements of increasing tumor depth, an established prognosticator of more aggressive disease. Notably, there was a significant linear trend between increasing depth as established by AJCC guidelines and increasing rates of PD-L1 expression. These results could suggest that, in DM, PD-L1 expression may be associated with more aggressive disease. It has been shown that PD-L1 expression in melanomas may be an adaptive response to IFN-γ secretion by CD8+ tumorinfiltrating lymphocytes. 17, 29 Given our finding that CD8+ tumor-infiltrating lymphocyte status was correlated with a maximum tumor depth 41 mm, an alternative explanation for the increased PD-L1 expression found in more invasive melanomas may be that it is an example of this adaptive response to IFN-γ secretion by CD8+ tumor-infiltrating lymphocytes found more frequently in deeply invading tumors. This interpretation is repudiated by the finding that, in our multivariate analysis, the association between tumoral PD-L1 expression and maximum tumor depth 41 mm was independently associated with PD-L1 expression even after controlling for CD8+ tumor-infiltrating lymphocyte status, which also remained significant. Aside from depth and CD8+ tumor-infiltrating lymphocyte status, perineural invasion was associated with tumoral PD-L1 expression (Table 1) . However, this association was not significant after multivariate analysis. One possible explanation is that, as we have found previously, perineural invasion is associated with deeper DMs as these tumors are more likely to encounter nerve fibers at greater depths, hence the multivariate analysis controlled for the confounding influence of depth resulting in a loss of significance. 7, 33 The mixed and pure variants of DM differ not only in morphology but also in prevalence of select oncogenic mutations and in prognosis. [5] [6] [7] [8] [9] [10] The mixed variant is associated with both an increased rate of lymph node metastases and is enriched for known activating mutations in oncogenes. 10 These differences suggest that the etiopathogenesis of pure DM and mixed DM may be distinct. After controlling for potential confounders in a multivariate analysis, we found that there was a greater than fivefold increase in the likelihood of PD-L1 expression in the mixed DM compared with pure DM. This association prompted us to re-evaluate cases of mixed DM to ascertain whether the pattern of PD-L1 staining was restricted to either the desmoplastic or conventional component of these tumors. We found that, of the mixed DMs that scored positive for PD-L1 expression, 17/22 (77%) displayed staining confined to the conventional component and that all 22 of the PD-L1-positive mixed DMs were of the conventional melanoma predominant subcategory of mixed DM (Figure 3) . The confinement of PD-L1 expression to the conventional component in the mixed cytomorphological variant together with the increased frequency of PD-L1 positivity in the mixed vs the pure subtype (as seen on multivariable analysis) underscores differences in adaptive immune resistance between the epithelioid and spindled melanoma phenotypes. The decreased propensity for lymph node metastasis in the pure subtype of DM suggests that PD-L1 expression may be a surrogate indicator of the more aggressive subtypes. Further underscoring the biological differences between desmoplastic subtypes is the genetic analyses by Jahn et al 10 showing that pure DM is more likely to display mutations in tumor-suppressor genes rather than oncogenes or to contain no known mutations, while the mixed subtype exhibited activating mutations in common conventional melanoma oncogenes (BRAF, NRAS, FGFR2, and ERBB2) albeit at a reduced rate. Our prior genetic analyses of DM has also revealed significant differences in the subtypes, with a higher proportion of cases of the mixed subtype exhibiting telomerase reverse transcripter promoter mutations. 9 Our prior immunohistochemical analyses of DM has shown that the mixed subtype displays a significantly increased Ki-67 proliferative rate and increased expression of the oncogene KIT when compared with the pure subtype and that neurofibromin loss is more common in the pure subtype. 6, 8 Taken together with findings from the current study, these studies underscore that the DM subtypes have distinct genetic drivers.
Although the prognostic relevance of PD-L1 expression on its own may be equivocal, it is becoming clear that there is value in determining the presence of tumoral PD-L1 for predicting response to anti-PD1/PD-L1 immunotherapy. 14, 15, 34 However, it should be noted that responses to anti-PD1/PD-L1 therapy have been observed in some cases of PD-L1-negative melanoma of a variety of subtypes. 35 Some have argued that, because CD8+ tumor-infiltrating lymphocytes are able to induce PD-L1 expression in tumor cells via IFN-γ secretion, PD-L1 serves as a marker of an on-going CD8+ cytotoxic antitumor reaction and the subsequent adaptive immune resistance response in the tumor. 17, 29 The concept of adaptive immune resistance may be important in establishing predictors to anti-PD1/PD-L1 therapy as Temeh et al 17 found that the presence of CD8+ tumor-infiltrating lymphocytes in conjunction with PD-L1 expression in pretreatment biopsies predicted response to anti-PD1/PD-L1 therapy in metastatic melanomas of unspecified subtype. We found that, in both our univariate and multivariate analysis, PD-L1 expression is associated with a positive CD8+ tumorinfiltrating lymphocyte status in DM-indicative of an adaptive immune resistance phenomenon in DM.
PD-L2 is a homolog of PD-L1 and also acts as a ligand to PD1 that inhibits the activation of cytotoxic CD8+ tumor-infiltrating lymphocytes. 36 Although we did observe tumoral PD-L2 expression in 52% of DMs studied, we did not find any significant correlation between PD-L2 and PD-L1 or with PD-L2 and CD8+ tumor-infiltrating lymphocyte status. Tumoral PD-L2 expression did not correlate with any other histopathological or genetic variable studied. We did observe a marginal correlation between tumoral PD-L2 expression and ulceration (P = 0.0667). However, we are likely underpowered to detect the true effect of ulceration on PD-L2 expression as only 1/38 samples were both ulcerated and lacked PD-L2 expression. It is unlikely that the seven non-ulcerated cases that failed to stain for PD-L2 are differentially biasing the results. Therefore, this study may be an underestimate of the true association between ulceration and PD-L2 and future research is warranted. The role of PD-L2 in adaptive immune resistance and in predicting response to immune checkpoint blockade is currently unknown. Taube et al 18 found in a study of multiple cancer types, including melanomas (type unspecified), that PD-L2 expression correlated with PD-L1 status. However, we found no such correlation in DM, a finding that further underscores differences between DM and conventional melanoma.
Future investigations into the pathological and prognostic role of PD-L1/PD-L2 expression in DM may benefit from the use of patient-matched biopsies of both primary and metastatic lesions. As anti-PD1/ PD-L1 therapy is used in the setting of metastatic disease, PD-L1 positivity in biopsies from metastatic sites may be more predictive of response. Currently, many studies that have investigated the predictive value of PD-L1 expression for anti-PD1/PD-L1 therapy have not differentiated between primary and metastatic biopsies. 14, 17 Taube et al 29 have shown that there are similar rates of PD-L1 positivity in primary and metastatic biopsies (not patient matched) in the setting of conventional melanoma. Although a larger study by Madore et al 27 found that in patient-matched melanoma biopsies PD-L1 expression was discordant between primary and metastatic lesions. Given the higher frequency of lymph node involvement in the mixed subtype together with findings from the current study, it is our contention that matched samples of the mixed cytomorphological variant are likely to demonstrate a similar PD-L1 profile. Although this observation requires further study and validation on larger sample sizes of mixed DM cases as well as matched samples, it may in part begin to explain the significant phenotypic differences between these two groups. Finally, although ours is the largest study on PD-L1 expression in primary DM, given the relative rarity of DM, sample size remains a limitation. Nonetheless, given the marginally significant (P = 0.0644) association on univariate analysis of PD-L1 expression with the mixed desmoplastic subtype, it is possible to hypothesize, from a scientific perspective alone, that such an association would achieve statistical significance with a larger cohort.
In conclusion, findings from the current study of a correlation of tumoral PD-L1 with increased depth of invasion, as well as the presence of CD8+ lymphocytes, implicate the tumoral immune microenvironment with advancing disease in DM. More importantly, our findings provide a biological explanation for the recent observation that patients with metastatic DM respond more favorably to anti-PD1/ PD-L1 therapy than other melanoma subtypes. Enhanced tumoral PD-L1 expression in mixed DM provides an insight into the differential pathogenesis of the subtypes and suggests that DM patients with this cytomorphological variant are likely better candidates for anti-PD/PD-L1 therapy.
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